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Objective: To evaluate the prevalence of hepatitis C virus (HCV) genotypes in  a central area of Italy (Umbria); to analyze 
the correspondence of the genotypes detected in serum and liver samples; t o  study the relationship between HCV 
genotypes and severity of liver disease; t o  test whether co-infection with more than one HCV subtype could be influenced 
by the source of infection. 
Methods: Genotyping by polymerase chain reaction with core-specific primers (Okamoto method) was performed in 
the serum and liver from 48 consecutive patients with histologically confirmed chronic C hepatitis. 
Results: HCV genotype 1 b was the prevalent strain and was not associated with more severe histologic damage. Data 
show a very good correspondence between genotypes identified in serum and liver specimens (91%). Mixed infections 
(with subtypes 1 b and 2a) correlated significantly with intravenous drug abuse ( p = O . O O l ) .  
Conclusion: We confirmed that subtype 1 b is prevalent in central Italy. Co-infection with more than one subtype is not 
rare in intravenous drug abusers. 
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INTRODUCTION 
Viruses have been classified into serotypes on the basis 
of their immunologic characteristics, but with the 
recent development of molecular biology, viruses can 
now be classified genotypically [ 1 1. 
The hepatitis C virus (HCV) genome exhibits 
considerable variations among different isolates [2,3]. 
O n  the basis of sequence Ivergences, different HCV 
genotypes have been identified [4-11]. There are 
various methods of HCV genotype detection, in- 
cluding serotyping by specific antibodies (12-1 41, type- 
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specific primers [9,15,16], reverse hybridization to 
subtype-specific probes [17,18], DNA sequencing 
[19-231 and genotyping using restriction fragment 
length polymorphism analysis [1,22]. The different 
preliminary classifications of HCV [8,15,19] have been 
replaced by a proposed consensus system for nonien- 
clature based on sequence homology of at  least two 
genoniic regions, with phylogenetic tree analysis 
[23,24]. This classification allows differentiation of 
HCV into at least six major types, divided into distinct 
subtypes. For clarity, in this paper the proposed 
nomenclature has been used. 
HCV genotypes may differ in their biological 
effects, although these differences are still poorly under- 
stood. The clinical significance of infection with HCV 
genotypes and the geographic distribution is currently 
under investigation [25]. 
HCV genotyping might be important in clinical 
practice, since it has been suggested that subtype l b  is 
related to severity of liver disease [26,27] and poor 
response to interferon therapy 127-31). 
The aim of this study was to examine the HCV 
genotypes in patients with chronic C hepatitis, in order 
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to: (1) evaluate the prevalence of HCV genotypes in 
Uiiibria (central Italy); and (2) study the stratification 
of identified genotypes in relation to the route of 
infection, the serologic reactivity and the severity of 
liver damage. Furthermore, we investigated the corres- 
pondence of the genotypes isolated in sera and liver 
biopsy saniples, to test whether mixed infections i n  
patients with multiple exposures could be under- 
estimated by sera examination and whether cases with 
a single infection exist in which HCV R N A  can be 
detected only by liver biopsy. 
MATERIALS AND METHODS 
Patients 
Forty-eight consecutive patients (M/F= 28:20, mean 
age 45 years, range 25 to 70 years) from an area in 
central Italy (Uiiibria) with chronic hepatitis C,  
attending the Institute of Infectious Diseases of the 
University of Perugia, were studied. All patients were 
seropositive for anti-HCV enzyme irnmunoassay (EIA) 
(second-generation EIA test, Ortho Diagnostic System, 
Raritan, NJ, USA) and RIBA 11 (Chiron, Enieryville, 
CA, USA) and had persistently elevated serum alanine 
aniinotransferase (ALT) for at  least 1 year. The patients 
showed no evidence of alcoholic or drug-induced 
hepatitis. Sera were also exanlined for hepatitis B virus 
(HUV) and human immunodeficiency virus (HIV) 
(EIA coniniercially available kit, Abbott, Wiesbaden, 
Germany). They were histologically classified into 
three groups: chronic persistent hepatitis (CI'H), 
chronic active hepatitis (CAH) and chronic active 
hepatitis with cirrhosis (CAHC). 
The clinical, biochemical, virologic and histologic 
profiles of these patients are summarized in Table 1. 
Table 1 Clinicopathologic features of 48 patients 
~~ 
Malcs/FrmaleT 
Age (years) 
Epidemiologic risk: 
Transfusion 
Drug addictioii 
Unknown 
HBsAg + 
ALTq" 
Histology 
CPH 
CAH 
C A H C  
28:20 
45.1 t 1 5 . 6  
7/48 
13/48 
28/48 
1/48 
2.6 f 1.4 
19/48 
22/48 
7/48 
'ALTq = ALT quotient, the aLtual value iiieawred was divided by 
the tipper value of the normal range 
Samples 
Liver tissue was obtained by liver biopsy using a 
Menghini needle: the largest part of the fragment was 
fixed in fornialin for histologic exaniination and the 
remainder was immediately frozen at -7O'C: for RNA 
extraction. 
Sera samples from all subjects were frozen a t  
-7OOC until use. 
RNA extraction 
Total KNA was extracted from liver biopsy and from 
100 pl of serum using the acid phenol-guanidiun- 
thiocyanate method 1321. 
HCV RNA detection 
K N A  was reverse transcribed with 6.25 U of avian 
niyeloblastosis virus (AMV) (Promega, Madison WI; 
USA) in a volume of 20 p1 using specific antisense 
primer. A nested polymerase chain reaction (1CIL) 
method with primers deduced from the. conserved 5' 
noncoding region was used for detection of HCV 
ILNA [33], Precautions were taken to avoid carryover 
[34], and uegative controls were included in all 
experiments. The amplified products were analyzed by 
electrophoresis in 1.5% agarose gel and stained with 
e th idiuni bromide. 
HCV genotyping 
Genotypes were deterniined in positive saniples, using 
the Okanioto method, which amplifies core gene 
sequences with universal and four type-specific primers 
1151. This system allows the typing into four genotypes, 
types I to IV. Compared with the consensus nornew 
clature classification [23],  genotype I corresponds to 1 a ,  
I1 to lb, 111 to 2a, and IV to 2b, whereas type 3 was  not 
identified in this system. The primer described by Silini 
et a1 was used to identify the Italian 2a genotype 1351. 
Briefly, R N A  was denatured at 80°C for 2 inin 
and converted to cDNA in a mixture (final volume 
20 pl) containing 6.25 U of AMV, 20 U of RNAsiri 
(Proniega), 50 pniol of universal, antisense primer [ I  61, 
5 niM MgC12, 1 niM deoxynucleoside triphosphatc, 
and 1 x RT buffer (Proniega). After inactivation of 
AMV at 99 OC: for 5 niin, the cI>NA was amplified with 
2.5 U of AnipliTaq DNA polymerase (Perkin Elmer 
Cetus, Nonvalk, CT, GSA). 
PCR was carried out in a DNA thermal cycler 480 
(Perkin Elmer Cetus) with temperature and cycle5 
previously described [15]. The amplified products were 
analyzed by gel electrophoresis in 10%) polyacrylamide 
and stained with ethidiuni bromide. Genotypes were 
distinguished by the size of ainplicons, determined by 
coniparison with appropriate molecular size markers 
(I-kb DNA Ladder GI13CO BKL, Bethesda, MI), 
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Table 2 Prevalence of HCV genotypes in Feruni and liver 
biopsieq 
Genotype Seruiii Liver 
l b  21/45 (46.7%) 19/46 (41.3%) 
2a 34/45 (3I.lYi) 13/46 (28.3%) 
2b 1/45 (2.2%) 1 /4h (2.2%) 
lb+2a 7/45 (15.6%) 11/46 (23.9%) 
Not typed 2/45 (4.4%1) 2/46 (4.3’%’) 
Total samples 45 46 
USA). When double bands were observed, the result 
was confirmed by a second PCK with each of the four 
type-specific primers. 
Statistical analysis 
Categorial variables were analyzed with &-$quared 
test and, when appropriate, Fisher’s exact test. Odds 
ratio (OR) with 95% confidence intervals (CI) were 
also evaluated. 
Forty-six of the 48 liver biopsies (96%)) and 45 of the 
48 serum samples (93.7%) were positive for HCV 
RNA. Genotypes, determined in the positive samples, 
were identified in 44 biopsies and in 43 serum samples. 
The results are illustrated in Table 2. Type l b  had the 
highest prevalence, 62% in serum and 65% in liver 
biopsies, includmg the cases in which more than one 
genotype was present; type l a  was not detected and 
mixed infections (type l b  + 2a) were determined in 
23.9% of liver samples and in 15.6% of serum samples. 
In two cases (both positive for HCV R N A  in serum 
and liver samples), it was not possible to identify the 
viral genotype. There was a correlation between the 
genotypes identified in serum and liver samples, with 
the exception of four cases, in which a mixed infection 
Table 3 Comparison between genotypes 1 b and 2a 
Variable Genotype l b  Genotypc 2a 
n = 21 n = 1 4  
Sex = M 11 (52.3%)) 7 (50%)) 
Mean age (yr) 4s +_ 17 so f 14 
ALTq” 2.6f 1.6 2.1? 1.2 
Liver histology: 
CPH 11 (52.3%)) 3 (21.4%) 
CAHC 3 (14.2%) 2 (14.296) 
CAH 7 (33.3%) Y (64.2%) 
,‘ALTq=ALT quotient, the actual value measured was divided by 
the upper value of the normal range. 
Thcre were no ctatistically significant differences between the two 
groups. 
Table 4 Prevalence of mixed infections in IVDA 
Source of Patients Mixed infection 
infection n = 45 n=7 
IVDA 13 6 (46%) 
Non-IVDA 32 1 (3%1) 
p=O.OOl. 
(1b + 2a) was found in the liver, whereas only type 1 b 
(three cases) or 2a (one case) were detected in sera. In 
one case where serum HCV R N A  was negative, the 1 b 
genotype was identified in the liver sample only. We 
found no significant differences in the mean age, sex 
and mean serum aminotransferase concentration 
between subtypes l b  and 2a (Table 3). As shown in the 
table, there was no statistically significant correlation 
(p > 0.05) between the identified genotype and the 
severity of histologic damage. In particular, type l b  was 
not associated with a more severe hepatitis compared 
with 2a (Table 3). 
No correlation was found between genotypes and 
transfusion or unknown epidemiologic risk factors; 
however, mixed infections were significantly more 
frequent in intravenous drug abusers (IVUAs) (liver: 
p=0.005, OK=8.46, C1=1.49-50.72; serum: p =  
0.001, ORz26.57 ,  CI=2.39-1259.57) (Table 4). It 
should be noted that in 6 of 13 IVDA patients (46%) 
an infection due to I b  and 2a genotypes was confirmed 
in both serum and liver samples. The serologic 
reactivity of patients infected with genotype 2a showed 
significantly lower prevalence of specific antibodies 
to the viral region NS4 (p=O.01, ORz0 .12 ,  CI= 
0.02-0.8). 
DISCUSSION 
HCV, like almost all R N A  viruses, has a ‘quasispecies’ 
nature 1361 due to the relatively high mutation rate, 
with an estimated frequency of 0.9-1.92 x niuta- 
tiondnucleotide per year [2].  Distinct genotypes have 
been proposed on the basis of sequence differences, 
and it is important to clarify whether specific HCV 
genotypes correlate with pathogenicity, infectivity, 
response to antiviral therapy and geographic prevalence 
137,381. 
Although sequence analysis is currently the optimal 
way of typing HCV, it is laborious and time- 
consuming, and thus difficult to apply to large-scale 
studies. 
In this study a comparative molecular investigation 
of HCV genotypes in liver and serum samples was 
performed on patients with chronic hepatitis C ,  using 
a PCR method with type-specific priniers 1151. 
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The majority of published reports refer to HCX 
genotypes isolated from serum or plasma; type Ib  is 
found predominantly in Europe I 271, whereas type 1 a 
is relatively rare, with the exception of hemophiliac 
patients 127,391. Superinfection with different strains of 
HCV together with chronic HCV carriage has been 
demonstrated in chimpanzees [ 401. The prevalence of 
mixed HCV infections is between 2% and 50'%1, 
depending 011 the genotyping method and patients 
selected I 1 5,27,30,41-44]. However, in a few cases 
HCY KNA could be detected only in hepatic tissue, 
and not in scruni 1451. I t  i s  not known whether data 
on genotypes identified from serum samples are also 
valid for hepatic samples. Thus, we evaluated whether 
patients exposed to repeated risk factors for HCV 
infection could host more than one virus in  the liver. 
The I-esults showed that the PCR typing assay, used 
in this study, i s  easy to perform and efficient in 
determining the four major subtypes of HCV (la ,  lb,  
2a, 2b) in liver and serum specimens. Our data show a 
very good correlation between genotypes identified in 
sera and liver specinlens (91%). 
Type l b  was the dominant strain, in agreement 
with other Italian reports 127,391, and does not 
correlate with severe hepatitis (Table 3). However, an 
accurate comparison was not possible, because the 
majority of patients had acquired the disease by 
inapparent transmission (51;%), making it iinpossible to 
deterniine the beginning of liver infection. As 
expected, type l a  was not detected in our patients, 
among whom there were no hemophiliacs. 
Mixed infections were found in 23.9% of liver 
saiiiples and in 15.6% of serum samples, and 
significantly correlated with intravenous drug abuse 
(Table 4). IVDAs may be exposed to recurrent HCV 
infections through needle sharing. Our findings suggest 
that co-infection with more than one HCV subtype 
nray be fi-equent in IVLlAs with chronic C hepatitis, 
and this is in accordance with a recent report [44]. 
Widell et al. [ Ih]  reported that the original 
Okamoto system yields in several sera double or triple 
bands, and could overestiiiiate multiple infections. 
However, in this study the good concordance of niixed 
infections in liver and serum samples, and their 
segregation with IVDA, are against the possibility of 
Eilse-positive results. 
The significance of mixed infections is currently 
unclear. HCV co-infection may play an iiiiportant role 
in the course of chronic C hepatitis [41], and in 
response to interferon therapy [ 461. Treatment with 
interferon may be associated with the appearance of 
resistant genotypes. The emergence of a new doniiiiant 
genotype may accelerate the progression of liver disease 
[46]. 
The control of HCV R N A  111 the liver and the 
detection of a viral genotype could help in verifying 
the clearance of the virus in responder patients 147,481, 
and the emergence of interferon-re~istant stlains 
146,491. 
Prospective studies are required to analyze the 
clinical and therapeutical imphcatioiis of different 
genotypes and HCV co-infections. 
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